TOPIC

Validation of B’SYS KV3.x cell lines using automated and manual patch-clamp electrophysiology

Journal

ICMS 2019 US

Author(s)

Ellen Braksator, Martina Bamberg, Jonathan Schuster, Julie Coulot, Daniel Konrad

Year

2019

KV3.x receptors have recently emerged as potential targets for treatment of a variety of CNS disorders, including epilepsy, ataxias, hearing disorders, schizophrenia and cognitive impairments. KV3.1–KV3.4 protein isoforms contribute to the high-frequency firing of neurons such as auditory brain stem neurons, fast-spiking cortical and hippocampal GABAergic interneurons, and Purkinje cells of the cerebellum, and play an important role in the regulation of intrinsic excitability and neurotransmitter release at presynaptic terminals of many neurons.

B’SYS has generated a panel of cell lines stably transfected with KV3.1a/b, KV3.2, KV3.3 and KV3.4 subunits. Using automated (QpatchTM ) as well as manual patch-clamp recordings, the aim of this validation study was to characterize these cell lines pharmacologically using the selective serotonin
reuptake inhibitor paroxetine. In addition, the effect of KV modulator 1 was investigated on KV3.1b.

Go to journal

Get in Touch

We strive to provide the best for our customers, and we are always ready to help. Please let us know if you have a question for us.

Follow us